Evolus Inc (EOLS)

Jun 15, 2026

[EFFECT] Evolus, Inc. SEC Filing - Stock Titan

Jun 15, 2026

Jun 14, 2026

Understanding the Setup: (EOLS) and Scalable Risk - Stock Traders Daily

Jun 14, 2026

Jun 12, 2026

Evolus shareholders re-elect directors and approve executive compensation By Investing.com - Investing.com Nigeria

Jun 12, 2026

Jun 12, 2026

Evolus (EOLS) shareholders approve directors, auditor and say-on-pay at 2026 meeting - Stock Titan

Jun 12, 2026

Jun 11, 2026

Evolus, Inc. (EOLS) reports Q1 loss, tops revenue estimates - MSN

Jun 11, 2026

Jun 08, 2026

Mizuho Securities Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $15 - Moomoo

Jun 08, 2026

Jun 05, 2026

Evolus (NASDAQ: EOLS) registers $250M shelf; $195.5M unsold re‑registered - Stock Titan

Jun 05, 2026

Jun 04, 2026

EOLS: Virtual Meeting with Management Scheduled on June 11 - GuruFocus

Jun 04, 2026

Jun 04, 2026

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society - GlobeNewswire Inc.

Jun 04, 2026

Jun 03, 2026

The Technical Signals Behind (EOLS) That Institutions Follow - Stock Traders Daily

Jun 03, 2026

Jun 03, 2026

Evolus (EOLS) Q2 2025 Earnings Call Transcript - AOL.com

Jun 03, 2026

Jun 02, 2026

Evolus Shareholder Notice - TMX Newsfile

Jun 02, 2026

Jun 02, 2026

Evolus Update - TMX Newsfile

Jun 02, 2026

Jun 02, 2026

Evolus Class Action Reminder - TMX Newsfile

Jun 02, 2026

Jun 02, 2026

Evolus Shareholder Alert - TMX Newsfile

Jun 02, 2026

May 28, 2026

Earnings call transcript: Evolus Inc Q1 2026 misses EPS forecast, stock rises - Investing.com Nigeria

May 28, 2026

May 23, 2026

Precision Trading with Evolus Inc. (EOLS) Risk Zones - Stock Traders Daily

May 23, 2026

May 20, 2026

Evolus Q1 2026 earnings preview - MSN

May 20, 2026

May 19, 2026

Evolus to Participate in The Jefferies Global Healthcare Conference - Business Wire

May 19, 2026

May 16, 2026

Evolus To Roll Out Estyme Injectable Hyaluronic Acid Fillers in Europe - The Dermatology Digest

May 16, 2026

May 15, 2026

TradingKey - TradingKey

May 15, 2026

May 14, 2026

Evolus Completes Key NUCEIVA Safety Study, Easing Risk for Aesthetic Toxin Investors - TipRanks

May 14, 2026

May 11, 2026

Evolus (EOLS) to Launch Estyme Injectable Collection in Europe - GuruFocus

May 11, 2026

May 11, 2026

Evolus to launch Estyme dermal filler line in Europe on May 16 - Investing.com UK

May 11, 2026

May 11, 2026

Evolus to Launch Estyme Dermal Fillers in Europe - Orange County Business Journal

May 11, 2026

May 11, 2026

Evolus to launch Estyme dermal filler line in Europe on May 16 By Investing.com - Investing.com South Africa

May 11, 2026

May 11, 2026

Evolus, Inc. Launches Estyme Injectable Hyaluronic Acid Gels Collection in Europe - marketscreener.com

May 11, 2026

May 11, 2026

Evolus launches Estyme in Europe with commercial debut targeted for May 16 - Traders Union

May 11, 2026

May 11, 2026

Evolus Announces Commercial Launch Of Estyme® Injectable Hyaluronic Acid Gels In Europe - TradingView

May 11, 2026

May 11, 2026

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe - ChartMill

May 11, 2026

May 11, 2026

What is HC Wainwright's Estimate for Evolus Q2 Earnings? - MarketBeat

May 11, 2026

May 11, 2026

Evolus May 2026 slides: HA innovation, Jeuveau data support dual strategy - Investing.com Australia

May 11, 2026

May 10, 2026

Evolus May 2026 slides: HA innovation, Jeuveau data support dual strategy By Investing.com - Investing.com South Africa

May 10, 2026

May 08, 2026

Evolus | 4: Statement of changes in beneficial ownership of securities-Officer MOATAZEDI DAVID - Moomoo

May 08, 2026

May 08, 2026

How sustainable is Evolus (EOLS) profit margins? (Bullish Sentiment) 2026-05-08Support Level Bounce - The Legal Advocate

May 08, 2026

May 07, 2026

Evolus, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:EOLS) 2026-05-07 - Seeking Alpha

May 07, 2026

May 07, 2026

Evolus reiterates 2026 net revenue of $327M-$337M while targeting a low to mid-single-digit adjusted EBITDA margin - MSN

May 07, 2026

May 06, 2026

Evolus Earnings Call Highlights Profitable Growth Path - TipRanks

May 06, 2026

May 06, 2026

Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Evolus (EOLS) - The Globe and Mail

May 06, 2026

May 06, 2026

Evolus Faces Heightened Operational Risk from Overseas Manufacturing and Disaster Recovery Gaps - TipRanks

May 06, 2026

May 05, 2026

PREVIEW-Weight-loss revolution sparks new appetite for aesthetics firms - Sahm

May 05, 2026

May 05, 2026

Stifel Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $17 - Moomoo

May 05, 2026

May 05, 2026

A Quick Look at Today's Ratings for Evolus(EOLS.US), With a Forecast Between $13 to $17 - Moomoo

May 05, 2026

May 05, 2026

Evolus, Inc. (NASDAQ:EOLS) Q1 2026 Earnings Call Transcript - Insider Monkey

May 05, 2026

May 05, 2026

Evolus, Inc. 2026 Q1 Financial Report: Key Risks, Financials, and Business Updates - Minichart

May 05, 2026